This EGRX PE ratio history page last updated 3/18/2024
Period | Price | Earnings | TTM | PE |
Q2 2023 8/8/2023 | 22.88 | 1.18 | 4.66 | 4.9 | Q1 2023 5/9/2023 | 25.29 | 1.26 | 5.04 | 5.0 | Q4 2022 3/13/2023 | 25.51 | 1.10 | 7.82 | 3.3 | Q3 2022 11/7/2022 | 39.73 | 1.12 | 7.57 | 5.2 | Q2 2022 8/9/2022 | 36.86 | 1.56 | 7.01 | 5.3 | Q1 2022 5/9/2022 | 42.95 | 4.04 | 6.38 | 6.7 | Q4 2021 3/7/2022 | 47.75 | 0.85 | 2.58 | 18.5 | Q3 2021 11/9/2021 | 51.40 | 0.56 | 2.69 | 19.1 | Q2 2021 8/9/2021 | 47.84 | 0.93 | 3.30 | 14.5 | Q1 2021 5/10/2021 | 38.47 | 0.24 | 2.94 | 13.1 | Q4 2020 3/2/2021 | 40.40 | 0.96 | 3.54 | 11.4 | Q3 2020 11/2/2020 | 49.22 | 1.17 | 3.06 | 16.1 | Q2 2020 8/10/2020 | 43.26 | 0.57 | 2.15 | 20.1 | Q1 2020 5/11/2020 | 54.57 | 0.84 | 2.42 | 22.5 | Q4 2019 3/2/2020 | 41.86 | 0.48 | 2.59 | 16.2 | Q3 2019 11/12/2019 | 58.34 | 0.26 | 3.31 | 17.6 | Q2 2019 8/8/2019 | 56.93 | 0.84 | 4.23 | 13.5 | Q1 2019 5/7/2019 | 56.95 | 1.01 | 4.34 | 13.1 | Q4 2018 2/28/2019 | 50.07 | 1.20 | 3.86 | 13.0 | Q3 2018 11/1/2018 | 52.23 | 1.18 | 3.66 | 14.3 | Q2 2018 8/7/2018 | 77.40 | 0.95 | 3.70 | 20.9 | Q1 2018 5/10/2018 | 62.38 | 0.53 | 3.24 | 19.3 | Q4 2017 2/26/2018 | 60.92 | 1.00 | 4.13 | 14.8 | Q3 2017 11/8/2017 | 57.58 | 1.22 | 5.82 | 9.9 | Q2 2017 8/9/2017 | 49.15 | 0.49 | 5.33 | 9.2 | Q1 2017 5/8/2017 | 86.34 | 1.42 | 5.64 | 15.3 | Q4 2016 3/1/2017 | 76.24 | 2.69 | 4.16 | 18.3 | Q3 2016 11/9/2016 | 81.73 | 0.73 | 1.54 | 53.1 | Q2 2016 8/9/2016 | 55.43 | 0.80 | 0.16 | 346.4 | Q1 2016 5/9/2016 | 40.09 | -0.06 | -1.17 | NA | Q4 2015 2/25/2016 | 66.30 | 0.07 | 0.20 | 331.5 | Q3 2015 11/11/2015 | 72.39 | -0.65 | -0.78 | NA | Q2 2015 8/11/2015 | 79.22 | -0.53 | -0.34 | NA | Q1 2015 5/12/2015 | 59.54 | 1.31 | -0.17 | NA | Q4 2014 12/17/2014 | 12.98 | -0.91 | NA | NA | Q3 2014 8/11/2014 | 10.99 | -0.21 | NA | NA | Q2 2014 5/14/2014 | 9.76 | -0.36 | NA | NA |
|
Period | Price | Earnings | Annualized | PE |
Q2 2023 8/8/2023 | 22.88 | 1.18 | 4.72 | 4.8 | Q1 2023 5/9/2023 | 25.29 | 1.26 | 5.04 | 5.0 | Q4 2022 3/13/2023 | 25.51 | 1.10 | 4.40 | 5.8 | Q3 2022 11/7/2022 | 39.73 | 1.12 | 4.48 | 8.9 | Q2 2022 8/9/2022 | 36.86 | 1.56 | 6.24 | 5.9 | Q1 2022 5/9/2022 | 42.95 | 4.04 | 16.16 | 2.7 | Q4 2021 3/7/2022 | 47.75 | 0.85 | 3.40 | 14.0 | Q3 2021 11/9/2021 | 51.40 | 0.56 | 2.24 | 22.9 | Q2 2021 8/9/2021 | 47.84 | 0.93 | 3.72 | 12.9 | Q1 2021 5/10/2021 | 38.47 | 0.24 | 0.96 | 40.1 | Q4 2020 3/2/2021 | 40.40 | 0.96 | 3.84 | 10.5 | Q3 2020 11/2/2020 | 49.22 | 1.17 | 4.68 | 10.5 | Q2 2020 8/10/2020 | 43.26 | 0.57 | 2.28 | 19.0 | Q1 2020 5/11/2020 | 54.57 | 0.84 | 3.36 | 16.2 | Q4 2019 3/2/2020 | 41.86 | 0.48 | 1.92 | 21.8 | Q3 2019 11/12/2019 | 58.34 | 0.26 | 1.04 | 56.1 | Q2 2019 8/8/2019 | 56.93 | 0.84 | 3.36 | 16.9 | Q1 2019 5/7/2019 | 56.95 | 1.01 | 4.04 | 14.1 | Q4 2018 2/28/2019 | 50.07 | 1.20 | 4.80 | 10.4 | Q3 2018 11/1/2018 | 52.23 | 1.18 | 4.72 | 11.1 | Q2 2018 8/7/2018 | 77.40 | 0.95 | 3.80 | 20.4 | Q1 2018 5/10/2018 | 62.38 | 0.53 | 2.12 | 29.4 | Q4 2017 2/26/2018 | 60.92 | 1.00 | 4.00 | 15.2 | Q3 2017 11/8/2017 | 57.58 | 1.22 | 4.88 | 11.8 | Q2 2017 8/9/2017 | 49.15 | 0.49 | 1.96 | 25.1 | Q1 2017 5/8/2017 | 86.34 | 1.42 | 5.68 | 15.2 | Q4 2016 3/1/2017 | 76.24 | 2.69 | 10.76 | 7.1 | Q3 2016 11/9/2016 | 81.73 | 0.73 | 2.92 | 28.0 | Q2 2016 8/9/2016 | 55.43 | 0.80 | 3.20 | 17.3 | Q1 2016 5/9/2016 | 40.09 | -0.06 | -0.24 | NA | Q4 2015 2/25/2016 | 66.30 | 0.07 | 0.28 | 236.8 | Q3 2015 11/11/2015 | 72.39 | -0.65 | -2.60 | NA | Q2 2015 8/11/2015 | 79.22 | -0.53 | -2.12 | NA | Q1 2015 5/12/2015 | 59.54 | 1.31 | 5.24 | 11.4 | Q4 2014 12/17/2014 | 12.98 | -0.91 | -3.64 | NA | Q3 2014 8/11/2014 | 10.99 | -0.21 | -0.84 | NA | Q2 2014 5/14/2014 | 9.76 | -0.36 | -1.44 | NA |
|
On this page we presented the EGRX PE Ratio History information for Eagle Pharmaceuticals' stock.
The average EGRX PE ratio history based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 23.5. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average EGRX PE ratio history based on this TTM earnings result method is 36.4. Note: any PE calculations involving negative earnings were discarded as not meaningful.
Let's now compare this EGRX PE ratio history result, against the recent PE: when this page was posted on 3/15/2024, the most recent closing price for EGRX had been 6.05, and the most recent quarterly earnings result, annualized, was 4.72. Meanwhile, the most recent TTM earnings summed to 4.66. From these numbers, we calculate the recent EGRX PE on 3/15/2024 based on annualized quarterly EPS was 1.3. Based on EGRX's history, that recent PE is low relative to the historical average, with the recent PE 94.5% lower than the historical average PE across our data set for Eagle Pharmaceuticals. Looking at the recent EGRX PE on 3/15/2024 based on TTM EPS, we calculate the ratio at 1.3. Based on EGRX's history, that recent PE is low relative to the historical average, with the recent PE 96.4% lower than the average PE across our Eagle Pharmaceuticals data set with TTM EPS used in the calculation at each period.
Another interesting EGRX PE ratio history calculation we look at is to take the median earnings per share of the last four quarters for EGRX, and then annualize the resulting value... with that annualized number then being used in the PE calculation. To walk through this math for EGRX, we start with the past four EPS numbers and we first sort them from lowest to highest: 1.10, 1.12, 1.18, and 1.26. We then toss out the highest and lowest result, and then take the average of those two middle numbers — 1.12 and 1.18 — which gives us the median of 1.15. Basically the way to think about this 1.15 number is this: for the trailing four earnings reports, 1.15 marks the "middle ground" number where EGRX has reported a value higher than 1.15 half the time, and has reported a value lower than 1.15 half the time. Annualizing that median value then gets us to 4.6/share, which we use as the denominator in our next PE calculation. With 6.05 as the numerator (as of 3/15/2024), the calculation is then 6.05 / 4.6 = 1.3 as the EGRX PE ratio as of 3/15/2024, based on that annualized median value we calculated.
For self directed investors doing their due diligence on EGRX or any other given stock, valuation analysis for EGRX
can greatly benefit from studying the past earnings and resulting PE ratio history calculations. This type of study can
help inform an analysis as to whether the earnings trajectory over time and current versus historical average PE ratios
justify the current stock market value.
That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate
Eagle Pharmaceuticals PE ratio history — or the PE history for any stock in our coverage universe.
And in your continued research we hope you will be sure to check out the further links included for
next earnings dates and also historical earnings surprises history for EGRX. Thanks for visiting, and the next
time you need to research EGRX PE Ratio History or the PE ratio history for another stock, we hope our site
will come to mind as your go-to PE ratio history research resource of choice.